What was the overall market valuation of the UK thyroid disorder market in 2024?

The overall market valuation was $156.95 Million in 2024. Read More

What is the projected market valuation for the UK thyroid disorder market by 2035?

The projected valuation for 2035 is $247.92 Million. Read More

What is the expected CAGR for the UK thyroid disorder market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.24%. Read More

Which companies are considered key players in the UK thyroid disorder market?

Key players include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Novartis, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Amgen. Read More

What were the segment valuations for hypothyroidism and hyperthyroidism in 2024?

In 2024, the valuation for hypothyroidism was $100.0 Million to $160.0 Million, while hyperthyroidism ranged from $56.95 Million to $87.92 Million. Read More

What treatment options are available in the UK thyroid disorder market and their valuations?

Treatment options include medications valued at $70.0 Million to $110.0 Million, surgery at $40.0 Million to $60.0 Million, and radioactive iodine therapy at $46.95 Million to $77.92 Million. Read More

What routes of administration are utilized in the UK thyroid disorder market?

Routes of administration include intravenous at $20.0 Million to $30.0 Million, oral at $100.0 Million to $160.0 Million, and other methods at $36.95 Million to $57.92 Million. Read More

What are the end-user segments in the UK thyroid disorder market?

End-user segments include clinics valued at $30.0 Million to $48.0 Million, hospitals at $90.0 Million to $140.0 Million, and others at $36.95 Million to $59.92 Million. Read More

How does the market for medications compare to other treatment options in 2024?

In 2024, the market for medications was valued between $70.0 Million and $110.0 Million, indicating a strong preference compared to surgery and radioactive iodine therapy. Read More

What trends are anticipated for the UK thyroid disorder market in the coming years?

The market is likely to experience growth, with a projected valuation increase to $247.92 Million by 2035, driven by an expected CAGR of 4.24%. Read More

UK Thyroid Disorder Market

ID: MRFR/HC/55235-HCR

200 Pages

Satyendra Maurya

Last Updated: February 06, 2026

UK Thyroid Disorder Market Research Report: Size, Share, Trend Analysis By Types (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy, Surgery), By Route of Administration (Oral, Intravenous, others) and By End Users (Hospitals, Clinics, others) - Growth Outlook & Industry Forecast 2025 To 2035

UK Thyroid Disorder Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.24%

2024 Market Size$ 156.95 Million

2025 Market Size$ 163.6 Million

2035 Market Size$ 247.92 Million

Key Players

AbbVie

Bristol-Myers Squibb

Eli Lilly and Company

Merck & Co.

Novartis

Pfizer

Trends

Rising Awareness and Diagnosis
Advancements in Treatment Options
Telemedicine Integration

Opportunities

Rising Healthcare Expenditure
Government Initiatives and Support
Innovations in Diagnostic Technologies

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Hypothyroidism
  2. 4.1.2 Hyperthyroidism
2. 4.2 Pharmaceutical, BY Treatment (USD Million)
  1. 4.2.1 Medications
  2. 4.2.2 Surgery
  3. 4.2.3 Radioactive iodine therapy
3. 4.3 Pharmaceutical, BY Route of Administration (USD Million)
  1. 4.3.1 Intravenous
  2. 4.3.2 Oral
  3. 4.3.3 Other
4. 4.4 Pharmaceutical, BY End-User (USD Million)
  1. 4.4.1 Clinics
  2. 4.4.2 Hospitals
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Takeda Pharmaceutical Company (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY TREATMENT
4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 UK MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Thyroid Disorder Market Segmentation

UK Thyroid Disorder Market By Type (USD Million, 2025-2035)

Hypothyroidism
Hyperthyroidism

UK Thyroid Disorder Market By Treatment (USD Million, 2025-2035)

Medications
Surgery
Radioactive iodine therapy

UK Thyroid Disorder Market By Route of Administration (USD Million, 2025-2035)

Intravenous
Oral
Other

UK Thyroid Disorder Market By End-User (USD Million, 2025-2035)

Clinics
Hospitals
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”